Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label randomized trial of PA21 versus sevelamer in hemodialysis patients with hyperphosphatemia
2007-003565-40Phase 2Terminated
- Sponsor
- CSL Vifor
- Start
- Oct 2007
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Sucroferric oxyhydroxide in hyperphosphatemia and chronic kidney disease (CKD) (2 arms), sponsored by CSL Vifor. Primary endpoint: Achievement of controlled serum phosphate levels at end of treatment. Started Oct 2007; status: terminated.
02
Drugs
Sucroferric oxyhydroxide
03
Conditions
hyperphosphatemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on 2007-003565-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003565-40.